News & Updates

‘Triple-G’ obesity drug also targets NAFLD in phase II trial
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023 byAudrey Abella

In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).

‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023
Eosinophil levels do not influence outcomes with triple combo asthma inhaler
Eosinophil levels do not influence outcomes with triple combo asthma inhaler
07 Jul 2023

Treatment with fixed-dose asthma inhaler combination of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) helps improve lung function and reduce exacerbations as compared with MF/IND and fluticasone/salmeterol (FLU/SAL), regardless of baseline eosinophil levels, according to a post hoc analysis of the IRIDIUM study.

Eosinophil levels do not influence outcomes with triple combo asthma inhaler
07 Jul 2023
Jaktinib superior to hydroxyurea in myelofibrosis
Jaktinib superior to hydroxyurea in myelofibrosis
07 Jul 2023 byStephen Padilla

Jaktinib, a novel JAK and AVCR1 inhibitor, is more effective than hydroxyurea in patients with myelofibrosis, resulting in better spleen response with improved symptom response and less cytopenias, according to the results of a phase III study presented at EHA 2023.

Jaktinib superior to hydroxyurea in myelofibrosis
07 Jul 2023